Table 3 |
|||
| Models for initial and confirmatory testing of CD | |||
| Model | Initial test | Additional tests if initial test positive | Definitive test |
| A | TG2 IgA | None | Biopsy |
| B | TG2 IgA | HLA-DQ | Biopsy if HLA-DQ2.5/2.2/8+ |
| C | TG2 IgA | EMA and HLA-DQ | Biopsy if HLA-DQ2.5/2.2/8+ |
| D | TG2 IgA | If TG2 IgA > 10 × ULN, then EMA and HLA-DQ; otherwise none | None if TG2 IgA > 10 × ULN, EMA abnormal and HLA-DQ2.5/2.2/8+; otherwise biopsy |
| E | HLA-DQ | TG2 IgA; if TG2 IgA 1 to 3 × ULN, then EMA | Biopsy if TG2 IgA >3 × ULN or EMA abnormal |
| F | Composite TG2/DGP IgA/IgG | None | Biopsy |
| G | Composite TG2/DGP IgA/IgG | HLA-DQ | Biopsy |
| H | Composite TG2/DGP IgA/IgG | HLA-DQ, TG2 IgA, DGP-G and DGP-A | Biopsy if HLA-DQ2.5/2.2/8+ and either TG2 IgA or DGP-G or DGP-A abnormal |
Abbreviations: DGP, Deamidated gliadin-derived peptide; EMA, endomysial antibody; HLA, human leukocyte antigen; TG, transglutaminase; ULN, upper limit of normal.
Anderson et al.
Anderson et al. BMC Medicine 2013 11:188 doi:10.1186/1741-7015-11-188
